Clinical Trials Logo

Clinical Trial Summary

Holmium Laser Enucleation of the Prostate (HoLEP) is a size-independent treatment option for benign prostatic hypertrophy (BPH) as recommended by the American Urological Association (AUA) Guidelines. Loop diuretics (furosemide) have been given historically during the morcellation portion of HoLEP to promote urine production in the post-operative setting and to minimize the impact of fluid absorption during long periods of morcellation. The intra-operative use of 20mg IV furosemide in perioperative HoLEP pathways has been propagated with the dissemination of HoLEP across North America without evidence to support its routine administration. With increasing surgical efficiency from improvements in laser and morcellator technology, the role of intra-operative furosemide is unknown. This study is designed to assess if there is a significant difference in same day discharge rates after Holmium Laser Enucleation of the Prostate (HoLEP) with and without IV furosemide. .


Clinical Trial Description

Holmium Laser Enucleation of the Prostate (HoLEP) is a size-independent treatment option for benign prostatic hypertrophy (BPH) as recommended by the American Urological Association (AUA) Guidelines. Loop diuretics (furosemide) have been given historically during the morcellation portion of HoLEP to promote urine production in the post-operative setting and to minimize the impact of fluid absorption during long periods of morcellation. The intra-operative use of 20mg IV furosemide in perioperative HoLEP pathways has been propagated with the dissemination of HoLEP across North America without evidence to support its routine administration. This single-center randomized controlled trial is designed to assess if there is a significant difference in same day discharge rates after Holmium Laser Enucleation of the Prostate (HoLEP). We currently attempt to perform HoLEP as a same-day discharge (SDD) procedure, however one of the main limiting factors in SDD is hematuria. Loop diuretics (furosemide) have been administered at the time of morcellation as a part of our HoLEP pathway to increase post-operative urinary output and reduce clinically significant gross hematuria and clot-formation. The objective of our study will be to assess if SDD rates are non-inferior in those patients who do not receive furosemide diuretics versus those that do. Patients will be randomized 1:1 to 20mg of IV lasix versus control. Patients and the surgeon/post-operative care team (fellow, residents, and nursing team) will be blinded to the treatment allocation. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05620784
Study type Interventional
Source Northwestern University
Contact Nicholas S Dean, MD
Phone 7806906285
Email nicholas.dean@northwestern.edu
Status Recruiting
Phase Phase 3
Start date March 1, 2023
Completion date August 1, 2024

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02974751 - Global Post-Market Registry Using Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue
Terminated NCT04398966 - Prostatic Artery Embolization vs Medication for Benign Prostatic Hyperplasia N/A
Completed NCT04029012 - Penthrox in Rezūm BPH Phase 4
Recruiting NCT03912558 - Pilot Study to Assess the Safety and Efficacy of Butterfly Medical Prostatic Retraction Device in BPH Patients. N/A
Completed NCT00527488 - Explorative Study of Degarelix for Treatment of Benign Prostatic Hyperplasia. Phase 2
Recruiting NCT06323109 - US Imaging for the Assessment of LUTS
Completed NCT05628025 - Simulation-Based Enucleation Training: Initial Experience Using 3D-printed Organ Phantoms
Completed NCT00407329 - Urokinase Plasminogen Activator System in Benign Prostatic Hyperplasia N/A
Completed NCT00256399 - Uroxatral in Men With Benign Prostate Hypertrophy (BPH) and Erectile Dysfunction (ED) N/A
Terminated NCT03994263 - A Prospective Study to Observe the Mechanism of Action of the MediTate iTind in Subjects With Symptomatic BPH With MRI N/A
Completed NCT03772808 - Effects of LycoComfort™ Supplementation on Symptoms Associated With Lower Urinary Tract Symptoms (LUTS) N/A
Completed NCT05818670 - Comparison Between Tamsulosin and Tadalafil in Management of Benign Prostatic Hyperplasia Long Term Study Phase 4
Withdrawn NCT02961114 - Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy Phase 1/Phase 2
Active, not recruiting NCT04198103 - Transperineal Laser Ablation for Percutaneous Treatment of Benign Prostatic Hyperplasia N/A
Completed NCT00696761 - The Long Term Effects of Alfuzosin(Xatral XL) in Lower Urinary Tract Symptoms(LUTS)/BPH Patients Phase 4
Completed NCT00199550 - Bipolar vs Monopolar Transurethral Resection of the Prostate (TURP) Phase 4
Completed NCT02702947 - Efficacy of Prunus Domestica Extract in BPH Phase 4
Completed NCT00154843 - A Clinical Study to Determine Factors Affecting Absorption and Serum Levels of Lycopene After Supplementation Phase 2
Completed NCT00037141 - Safety/Tolerability Study of Alcohol Injection for Treatment of BPH (Enlarged Prostate) Phase 1/Phase 2
Not yet recruiting NCT05719220 - Effect of Group Preoperative Pelvic Floor Training for HoLEP